Leading experts on Environmental and Social Corporate Governance (ESG) joined an animated discussion in central Paris on 15th April, at an event hosted by PR Newswire. “Attracting Sustainable Investment” drew IR professionals from French issuers and agencies, interested in discussing the latest regulatory changes and trends in sustainability reporting.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7510051-prnewswire-convenes-european-experts/
Honeywell (NYSE:HON) today announced the next generation of smart building technology, Command and Control Suite, which turns complex facility data into recommendations and easy-to-implement changes that help boost business outcomes — lowering costs, minimizing risk and reducing downtime.
By combining intelligent automation, advanced analytics and visualization with the simplified user experience of today‘s home and mobile electronics, Command and Control Suite links building automation and the enterprise. It can provide a holistic view of a connected building‘s video feeds, access control and fire alarms, for example, and pull in relevant information from human resource applications. Integrating data from these disparate systems could help security personnel track occupants and make sure they exit the facility in the event of an evacuation, improving employee safety.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7525451-honeywell-command-and-control-suite/
Evidence from the Childhood Cancer Survivor Study suggests that changes in childhood cancer treatment have reduced deaths from the late effects of cancer treatment and extended the lives of childhood cancer survivors. St. Jude Children’s Research Hospital investigators led the research, which will be presented today at the plenary session of the 2015 annual meeting of the American Society of Clinical Oncology (ASCO).
The study is one of four being featured at the plenary session press briefing, which highlights research that ASCO deems as having the highest scientific merit and greatest potential to affect patient care.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7532851-st-jude-cancer-research/
Adlens, the global leader in adjustable focus eyewear, has launched its ground-breaking adjustable prescription eyewear ‘AdlensFocuss™’, the greatest advancement in optics in more than 50 years.
Vision inevitably changes with age and people often need different strength glasses to see at near, intermediate and far distances. Progressive lenses are an option but they have a restricted usable lens area. A GFK Roper Study has shown one-third of wearers say they have trouble adjusting to them with seven to eight percent of wearers saying they cannot adjust to them at all.
AdlensFocuss provides the benefits of a single vision lens – full frame viewing area – with the best features of a progressive lens – the ability to see at different distances. They are prescription glasses with proprietary technology; a unique flexible membrane that allows the power to be adjusted by simply turning small dials on the inside of the frames. AdlensFocuss lenses offer at least four times more viewing area than traditional progressive lenses and come encased in a fashion-forward frame from award-winning designer Blake Kuwahara.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7544851-adlensfocuss-optics-technology/
Sullivan & Cromwell announces the launch of a multi-part video series designed to share insights from senior S&C lawyers on trends and issues impacting global financial institutions. The interviews are conducted by Lee Pacchia, Founder and CEO of Mimesis Law. In the first segment, Mitch Eitel, Managing Partner of the S&C Financial Services Group, discusses the appearance of shareholder activism in the sector, the psychology that affects the industry and burdens on financial institutions from a range of Dodd Frank changes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7542531-sullivan-cromwell/
Today, GENYOUth announced the launch of Fuel Up to Play 60 en español, an evolution of its national flagship program. The program encourages Spanish-speaking communities nationwide to live healthier lifestyles through good nutrition and physical activity. Fuel Up to Play 60 launched a redesigned website (FuelUpToPlay60.com) that provides Spanish-language content and materials, extending the reach and access of the program to students, teachers and families across the country. Several organizations have supported the effort, including the PepsiCo Foundation, which has provided a previously announced grant of $550,000 to develop Spanish-language materials and resources. In addition the PepsiCo Foundation will provide another $100,000 for mini-grants for health and wellness activities and programming within Los Angeles Unified School District and Miami-Dade County Public Schools.
Fuel Up to Play 60, a program founded by the National Football League (NFL) and National Dairy Council (NDC), is designed to engage and empower youth to take action for their own health by implementing long-term, positive nutrition and physical activity changes for themselves, their schools and their communities. Studies show that physical fitness may benefit brain health and academic performance, suggesting active kids may do better. However, only 1 in 3 kids are active every day, potentially leaving many at a disadvantage inside and outside of the classroom.
To view the multimedia release go to:
http://www.multivu.com/players/English/7646551-fuel-up-to-play-60/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Kia Motors America (KMA) today unveiled the all-new 2017 Sportage at the Los Angeles Auto Show. The fourth-generation Sportage, KMA’s longest-running nameplate, wraps stunning contemporary design around a structure that is both stiffer and more spacious than before. Advanced driver assistance technologies, significant suspension and steering improvements, and available intelligent AWD vastly improve the Sportage’s driving dynamics while premium materials and world-class craftsmanship create a class-up experience in an otherwise utilitarian segment.
“Simply put, the Sportage is a breed apart in the compact CUV segment,” said Orth Hedrick, vice president, product planning KMA. “Instead of bland utility, the Sportage combines distinctly European and sporty styling with thoughtful design and functionality, including innovative packaging, premium materials, a turbocharged engine and surprising features. Sales of compact CUVs are on a sharply upward trajectory, and the all-new 2017 Sportage hits the sweet spot by providing an alternative for those seeking to express themselves with a vehicle that’s versatile enough to suit their unique lifestyle.”
The all-new Sportage’s roomier, more luxurious cabin features an impressive level of craftsmanship, with high-quality, soft-touch materials and a range of technologies improving overall comfort, convenience, and connectivity. Updates to the drivetrain provide enhanced efficiency and performance, while changes to the suspension deliver better ride and handling. Like the outgoing model, the all-new Sportage will be built at Kia’s production facility in Gwangju, Korea, and be available in three distinct trim levels (LX, EX, SX Turbo) when it goes on sale next year. Pricing will be announced closer to the Sportage’s on-sale date.
To view the multimedia release go to:
http://www.multivu.com/players/English/7436354-2017-kia-sportage-l-a-auto-show-debut/
Celebrating its fifth anniversary next year, the JNA Awards, the jewellery and gemstone industry's premier platform for recognising innovative and high-achieving individuals and enterprises, announces changes to its award categories.
The organiser of the event, JNA (Jewellery News Asia), has made adjustments to a few award categories to encourage greater participation from more regions and, at the same time, consolidate some categories that are judged against a similar set of criteria. In 2016, the JNA Awards will have 11 categories, including the Lifetime Achievement Award -- the recipient of which will be selected by the organiser.
Of the above-mentioned list, the two Manufacturer of the Year categories have been broadened to encourage wider stakeholder involvement from the manufacturing sector. The scope of the Outstanding Enterprise of the Year categories has also been expanded to inspire companies from regions outside of the ASEAN and Mainland China to join the awards.
To view the multimedia release go to:
http://www.multivu.com/players/English/7705051-jna-awards-2016/
Losing weight and being healthier are at the top of everyone’s New Year’s resolutions. But, despite the best intentions, work, kids, and social events often push lifestyle changes to the bottom of the list. While many are familiar with type 2 diabetes, fewer are aware of prediabetes, a serious health condition that affects 86 million Americans (more than 1 in 3) and often leads to type 2 diabetes. People with prediabetes have higher than normal blood glucose (sugar) levels, but not high enough yet to be diagnosed with type 2 diabetes.
To raise awareness and help people with prediabetes know where they stand and how to prevent type 2 diabetes, the American Diabetes Association (ADA), the American Medical Association (AMA), and the Centers for Disease Control and Prevention (CDC) have partnered with the Ad Council to launch the first national public service advertising (PSA) campaign about prediabetes. The PSA campaign, featuring first-of-its-kind communications techniques, was developed pro bono by Ogilvy & Mather New York for the Ad Council.
Nearly 90 percent of people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health, including type 2 diabetes, heart attack, and stroke. Current trends suggest that, if not treated, 15 to 30 percent of people with prediabetes will develop type 2 diabetes within five years. The good news is that prediabetes often can be reversed through weight loss, diet changes and increased physical activity. Diagnosis is key: research shows that once people are aware of their condition, they are much more likely to make the necessary lifestyle changes.
To view the multimedia release go to:
http://www.multivu.com/players/English/7731551-ad-council-prediabetes-psa/
